论文部分内容阅读
近几年来,北京市的中成药新药研究,取得了一定成果。如消栓通络片、骨刺消痛液等新药的研制取得了较好的经济效益。特别是在目前“中药材难购,中成药难销”的情况下,加强中成药新药的研究,更有重要的意义。本文就中成药新药研究的实际工作,谈些粗浅的意见和看法。一、新药新剂型的开发速度问题自1980年至1984年的五年时间里,北京市药材公司系统计划研究的新药约75个,完成18个,约占24%。从剂型上看,主要是片剂和大蜜丸。片剂有消栓通络片、罗黄降压片、健儿片、利咽灵片、小儿清肺止咳片、小儿感冒片、香苏调胃片等。大蜜九有消栓再造丸、安宫降压丸、心宝、坤宝等。其他的新药和剂型只有小儿化滞散、枣仁安眠液、益气健脑糖浆、骨刺消痛液等。由此可见,科研步伐还不快,新药新剂型的开发还赶不上市场的变化。在北京市常生产的400多种中成药中,老的传统品种占90%以上。足见新产品,新剂型的开发速度是不快的。
In recent years, the research of new Chinese medicines in Beijing has achieved certain results. For example, the development of new drugs such as Xiaoshuan Tongluo Tablets and Spurs Xiaotongshui has achieved good economic benefits. Especially in the current situation of “Chinese herbal medicines are difficult to purchase, hard to sell proprietary Chinese medicines”, it is more important to strengthen the research of new Chinese patent medicines. In this article, we will discuss some practical ideas about the research of new Chinese medicines and discuss some of them. First, the development speed of the new drug new dosage form In the five years from 1980 to 1984, there were about 75 new drugs researched and planned by Beijing Medicinal Materials Co., Ltd., and 18 were completed, accounting for about 24%. In terms of dosage form, tablets and Da Mi Wan are mainly used. Tablets include Xiaoshuang Tongluo Tablets, Luohuang Jiangya Tablets, Jianer Tablets, Liyanling Tablets, Pediatric Qingfei Cough Tablets, Pediatric Cold Masks, and Susong Tingwei Tablets. Da Mijiu has Xiaoshuan Zaizao Pills, Angong Jiangya Pills, Xinbao, Kunbao and so on. Other new medicines and dosage forms include only infantile stagnation, jujube sleep, Yinqi brain syrup, and bone spurs. From this we can see that the pace of scientific research is still not fast, and the development of new drugs and new formulations has not caught up with the changes in the market. Of the more than 400 proprietary Chinese medicines that Beijing produces, older traditional varieties account for more than 90%. It is clear that the development of new formulations is unpleasant.